Article Text

Download PDFPDF
Anti-interleukin antibodies for systemic juvenile idiopathic arthritis

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Systemic juvenile idiopathic arthritis (systemic JIA) is the most severe form of JIA, often with persistent chronic arthritis, joint damage, and disability along with systemic features (spiking fever, rash, hepatosplenomegaly, and serositis) and raised levels of markers of inflammation. High-dose steroid treatment is often toxic and other treatments such as methotrexate and tumour necrosis factor inhibitors are relatively ineffective. Interleukins 1 and 6 have been implicated in the pathogenesis and preliminary studies have shown clinical responses to antibodies against these interleukins. Now successive papers in the New England Journal of Medicine …

View Full Text


  • Competing interests None.

  • Provenance and peer review Not commissioned; externally peer reviewed.